Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Synaptogenix stock

Learn how to easily invest in Synaptogenix stock.

Synaptogenix is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Synaptogenix stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – SNPX. It's that simple.

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • Get $10 when you sign up and deposit $100

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Synaptogenix stock price (NASDAQ: SNPX)

Use our graph to track the performance of SNPX stocks over time.

Synaptogenix shares at a glance

Information last updated 2023-01-24.
Latest market close$1.05
52-week range$0.96 - $10.65
50-day moving average $3.65
200-day moving average $5.78
Wall St. target price$14.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.12

Buy Synaptogenix stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Synaptogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synaptogenix price performance over time

Historical closes compared with the close of $1.05 from 2023-01-25

1 week (2023-01-19) -4.55%
1 month (2022-12-23) -10.26%
3 months (2022-10-26) -84.76%
6 months (2022-07-26) -80.63%
1 year (2022-01-26) -86.11%
2 years (2021-01-26) -81.90%
3 years (2020-01-22) N/A
5 years (2018-01-22) N/A

Synaptogenix financials

Gross profit TTM $0
Return on assets TTM -30.32%
Return on equity TTM -49.27%
Profit margin 0%
Book value $3.90
Market capitalisation $7.7 million

TTM: trailing 12 months

Synaptogenix share dividends

We're not expecting Synaptogenix to pay a dividend over the next 12 months.

Have Synaptogenix's shares ever split?

Synaptogenix's shares were split on a 1:4 basis on 19 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synaptogenix shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Synaptogenix shares which in turn could have impacted Synaptogenix's share price.

Synaptogenix share price volatility

Over the last 12 months, Synaptogenix's shares have ranged in value from as little as $0.96 up to $10.65. A popular way to gauge a stock's volatility is its "beta".

SNPX.US volatility(beta: 1.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synaptogenix's is 1.8816. This would suggest that Synaptogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Synaptogenix overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Frequently asked questions

What percentage of Synaptogenix is owned by insiders or institutions?
Currently 14.588% of Synaptogenix shares are held by insiders and 6.933% by institutions.
How many people work for Synaptogenix?
Latest data suggests 4 work at Synaptogenix.
When does the fiscal year end for Synaptogenix?
Synaptogenix's fiscal year ends in December.
Where is Synaptogenix based?
Synaptogenix's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036
What is Synaptogenix's ISIN number?
Synaptogenix's international securities identification number is: US87167T2015

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site